A First-in-human Study to Evaluate Safety and Tolerability of Topical BPR277 in Healthy Volunteers, and Proof of Concept (PoC) Studies to Evaluate the Safety, Tolerability, and Efficacy of Topical BPR277 in Patients With Atopic Dermatitis and Netherton Syndrome

Trial Profile

A First-in-human Study to Evaluate Safety and Tolerability of Topical BPR277 in Healthy Volunteers, and Proof of Concept (PoC) Studies to Evaluate the Safety, Tolerability, and Efficacy of Topical BPR277 in Patients With Atopic Dermatitis and Netherton Syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs BPR 277 (Primary)
  • Indications Atopic dermatitis; Congenital ichthyosiform erythroderma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 May 2014 The phase of the trial changed from I/II to I, as reported by ClinicalTrials.gov record.
    • 20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Apr 2014 New source identified and integrated (European Clinical Trials Database: 2011-000917-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top